Author(s):
Lokhande Kranti Anant, Prachi Kanawade, Sonone Sumit
Email(s):
lokhandekranti1@gmail.com
DOI:
10.52711/2231-5659.2026.00029 
Address:
Lokhande Kranti Anant*, Prachi Kanawade, Sonone Sumit
Swastyadarpan Pratishthan’s, Shantiniketan College of Pharmacy, Dhotre Bk., Parner, Ahmednagar, MS., India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 2,
Year - 2026
ABSTRACT:
Schizophrenia is a severe mental illness that alters a person's way of thinking, feeling, and relating to the world, usually in a way that makes them appear to have lost contact with reality. This paper gives an overview of this intricate illness. We examine the three primary categories of symptoms: psychotic symptoms (such as hallucinations or delusions), negative symptoms (such as lack of motivation or emotion), and cognitive symptoms (which include difficulties in memory and attention). The review also briefly addresses the causes, with reference to genetics and brain structure, specifically imbalances in neurotransmitters such as dopamine. We discuss how clinicians come to diagnose the condition based on criteria from such guides as the DSM-5-TR and medical tests to exclude other problems. Treatment is the main emphasis, however. Schizophrenia treatment involves both medication and therapy. We outline the medications, with second-generation antipsychotics (SGAs) being the first-line treatment of choice because they produce fewer movement side effects than older medications, although they are associated with metabolic side effects. The review finishes outlining five specific antipsychotic medications—such as Clozapine, Risperidone, Haloperidol, describing how they act, what they are licensed to treat, and what the most common side effects are.
Cite this article:
Lokhande Kranti Anant, Prachi Kanawade, Sonone Sumit. Drugs used in Schizophrenia: A Literature Review. Asian Journal of Research in Pharmaceutical Sciences.2026; 16(2):186-0. doi: 10.52711/2231-5659.2026.00029
Cite(Electronic):
Lokhande Kranti Anant, Prachi Kanawade, Sonone Sumit. Drugs used in Schizophrenia: A Literature Review. Asian Journal of Research in Pharmaceutical Sciences.2026; 16(2):186-0. doi: 10.52711/2231-5659.2026.00029 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2026-16-2-14
REFERENCE:
1. Ma M, Shi Z, Chen Y, Ma X. Recovery journey of people with a lived experience of schizophrenia: a qualitative study of experiences. BMC Psychiatry. 2023 Jun 27; 23(1):468.
2. Arango C, Buitelaar JK, Correll CU, Díaz-Caneja CM, Figueira ML, Fleischhacker WW, Marcotulli D, Parellada M, Vitiello B. The transition from adolescence to adulthood in patients with schizophrenia: challenges, opportunities and recommendations. European Neuropsychopharmacology. 2022 Jun 1; 59:45-55.
3. Eisner E, Berry N, Bucci S. Digital tools to support mental health: a survey study in psychosis. BMC Psychiatry. 2023 Oct 7; 23(1):726.
4. Eisner E, Berry N, Bucci S. Digital tools to support mental health: a survey study in psychosis. BMC Psychiatry. 2023 Oct 7; 23(1):726.
5. Carruthers SP, Van Rheenen TE, Karantonis JA, Rossell SL. Characterising demographic, clinical and functional features of cognitive subgroups in schizophrenia spectrum disorders: a systematic review. Neuropsychology Review. 2022 Dec; 32(4):807-27.
6. Fusar‐Poli P, Estradé A, Stanghellini G, Venables J, Onwumere J, Messas G, Gilardi L, Nelson B, Patel V, Bonoldi I, Aragona M. The lived experience of psychosis: a bottom‐up review co‐written by experts by experience and academics. World Psychiatry. 2022 Jun; 21(2):168-88.
7. Mosolov SN, Yaltonskaya PA. Primary and secondary negative symptoms in schizophrenia. Frontiers in psychiatry. 2022 Jan 3; 12:766692.
8. McCutcheon RA, Keefe RS, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Molecular psychiatry. 2023 May; 28(5):1902-18.
9. Wahbeh MH, Avramopoulos D. Gene-environment interactions in schizophrenia: a literature review. Genes. 2021 Nov 23; 12(12):1850.
10. Luvsannyam E, Jain MS, Pormento MK, Siddiqui H, Balagtas AR, Emuze BO, Poprawski T. Neurobiology of schizophrenia: a comprehensive review. Cureus. 2022 Apr 8; 14(4).
11. Khalil M, Hollander P, Raucher-Chéné D, Lepage M, Lavigne KM. Structural brain correlates of cognitive function in schizophrenia: A meta-analysis. Neuroscience & Biobehavioral Reviews. 2022 Jan 1; 132:37-49.
12. Li S, Song J, Ke P, Kong L, Lei B, Zhou J, Huang Y, Li H, Li G, Chen J, Li X. The gut microbiome is associated with brain structure and function in schizophrenia. Scientific Reports. 2021 May 7; 11(1):9743.
13. Kowalec K, Lu Y, Sariaslan A, Song J, Ploner A, Dalman C, Hultman CM, Larsson H, Lichtenstein P, Sullivan PF. Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study. Molecular Psychiatry. 2021 Aug; 26(8):4487-95.
14. F Thomas Juster, Frank P Stafford. Journal of Economic Literature 29 (2), 471-522, 1991
15. First MB. DSM-5-TR® Handbook of Differential diagnosis. American Psychiatric Pub; 2024 Jan 29.
16. Nussbaum AM. The pocket guide to the DSM-5-TR™ diagnostic exam. American Psychiatric Pub; 2022 Mar 18.
17. Jakobsen KD, Frederiksen JN, Hansen T, Jansson LB, Parnas J, Werge T. Reliability of clinical ICD-10 schizophrenia diagnoses. Nordic Journal of Psychiatry. 2005 Jun 1; 59(3):209-12.
18. Ots T. The angry liver, the anxious heart and the melancholy spleen: The phenomenology of perceptions in Chinese culture. Culture, Medicine and Psychiatry. 1990 Mar; 14(1):21-58.
19. Häfner H, an der Heiden W. Epidemiology of schizophrenia. The Canadian Journal of Psychiatry. 1997 Mar; 42(2):139-51.
20. Messias EL, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatric Clinics of North America. 2007 Sep 1; 30(3):323-38.
21. Häfner H, Riecher-Rössler A, Der Heiden WA, Maurer K, Fätkenheuer B, Löffler W. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychological Medicine. 1993 Nov; 23(4):925-40.
22. Clozapine is an atypical or second-generation antipsychotic drug used in treatment-resistant schizophrenia and to decrease suicide risk in schizophrenic patients.
23. Wagner E, Loehrs L, Siskind D, Honer WG, Falkai P, Hasan A. Clozapine augmentation strategies–a systematic meta-review of available evidence. Treatment options for clozapine resistance. Journal of Psychopharmacology. 2019 Apr; 33(4):423-35.
24. Correll CU, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Seppälä N, Howes OD. A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia. CNS Drugs. 2022 Jul; 36(7):659-79.
25. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. History of Psychiatry. 2007 Mar; 18(1):39-60.
26. Borrelli EP, Lee EY, Caffrey AR. Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program. Mental Health Clinician. 2020 May 1; 10(3):70-5.
27. Adams CE, Awad GA, Rathbone J, Thornley B, Soares‐Weiser K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. 2014(1).
28. Lear E, Chiron AE, Pallin IM. A clinical study of mechanisms of action of chlorpromazine. Journal of the American Medical Association. 1957 Jan 5; 163(1):30-6.
29. López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry. 2005 Jan 1; 17(3):113-35.
30. Tufekcioglu Z, Bilgic B, Hanagasi H, Emre M. Management of motor symptoms in dementia disorders. InManagement of patients with dementia: The role of the physician 2021 Jul 27 (pp. 201-227). Cham: Springer International Publishing.
31. Adams CE, Bergman H, Irving CB, Lawrie S, Cochrane Schizophrenia Group. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. 1996 Sep 1; 2013(11).
32. Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neuroscience and Therapeutics. 2011 Apr; 17(2):97-103.
33. Vella-Brincat J, Macleod AD. Haloperidol in palliative care. Palliative Medicine. 2004 Apr; 18(3):195-201.
34. Yen YC, Lung FW, Chong MY. Adverse effects of risperidone and haloperidol treatment in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2004 Mar 1; 28(2):285-90.
35. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 1999 Mar 1; 52(4):782-.
36. Hartung B, Sampson S, Leucht S. Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews. 2015(3).
37. Zarate C, Gould T, Zanos P, Machado-Vieira R. 80. Theories on the Mechanism of Action of Ketamine: From NMDA Receptor Inhibition to the (2R, 6R)-HNK Metabolite. Biological Psychiatry. 2017 May 15; 81(10):S33-4.
38. Whittaker CB, Hoy RM. Withdrawal of perphenazine in chronic schizophrenia. The British Journal of Psychiatry. 1963 May; 109(460): 422-7.
39. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. The American Journal of Psychiatry. 1994 Jun.
40. Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neuroscience and Therapeutics. 2011 Apr; 17(2):97-103.
41. Cohen LJ. Risperidone. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1994 May 6; 14(3):253-65.
42. Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. Journal of Psychopharmacology. 1997 Jan; 11(1):65-71.
43. Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R. Metabolic side effects of risperidone in early onset schizophrenia. L’encephale. 2009 Dec 1; 36(3):242-52.